Adamalizyny jako potencjalne biomarkery w wybranych nowotworach złośliwych przewodu pokarmowego

[1]Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018; 68: 394-424 Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin 2018 68 394 42410.3322/caac.2149230207593Search in Google Scholar

[2]Duffy M.J., McKiernan E., O’Donovan N., McGowan P.M.: Role of ADAMs in cancer formation and progression. Clin. Cancer Res., 2009; 15: 1140-1144 Duffy M.J. McKiernan E. O’Donovan N. McGowan P.M. Role of ADAMs in cancer formation and progression Clin. Cancer Res 2009 15 1140 114410.1158/1078-0432.CCR-08-158519228719Search in Google Scholar

[3]Walkiewicz K., Kozieł P., Bednarczyk M., Błażelonis A., Mazurek U., Muc-Wierzgoń M.: Expression of migration-related genes in human colorectal cancer and activity of a disintegrin and metalloproteinase 17. Biomed Res. Int., 2016; 2016: 8208904 Walkiewicz K. Kozieł P. Bednarczyk M. Błażelonis A. Mazurek U. Muc-Wierzgoń M. Expression of migration-related genes in human colorectal cancer and activity of a disintegrin and metalloproteinase 17 Biomed Res. Int 2016 2016 820890410.1155/2016/8208904482667127110571Search in Google Scholar

[4]Walkiewicz K., Nowakowska-Zajdel E., Kozieł P., Muc-Wierzgoń M.: The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer. Cent. Eur. J. Immunol., 2018; 43: 109-113 Walkiewicz K. Nowakowska-Zajdel E. Kozieł P. Muc-Wierzgoń M. The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer Cent. Eur. J. Immunol 2018 43 109 11310.5114/ceji.2018.74881592718029731694Search in Google Scholar

[5]Fushida S., Oyama K., Kinoshita J., Yagi Y., Okamoto K., Tajima H., Ninomiya I., Fujimura T., Ohta T.: VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: Prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. Onco. Targets Ther., 2013; 6: 14451451 Fushida S. Oyama K. Kinoshita J. Yagi Y. Okamoto K. Tajima H. Ninomiya I. Fujimura T. Ohta T. VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: Prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody Onco. Targets Ther 2013 6 1445145110.2147/OTT.S51916380459124204159Search in Google Scholar

[6]Gao M.Q., Kim B.G., Kang S., Choi Y.P., Yoon J.H., Cho N.H.: Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-α cleavage by ADAM17. Cancer Lett., 2013; 336: 240-246 Gao M.Q. Kim B.G. Kang S. Choi Y.P. Yoon J.H. Cho N.H. Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-α cleavage by ADAM17 Cancer Lett 2013 336 240 24610.1016/j.canlet.2013.05.01123684931Search in Google Scholar

[7]Mochizuki S., Okada Y.: ADAM28 as a target for human cancers. Curr. Pharm. Des., 2009; 15: 2349-2358 Mochizuki S. Okada Y. ADAM28 as a target for human cancers Curr. Pharm. Des 2009 15 2349 235810.2174/13816120978868242419601836Search in Google Scholar

[8]Stawikowska R., Cudic M., Giulianotti M., Houghten R.A., Fields G.B., Minond D.: Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates. J. Biol. Chem., 2013; 288: 22871-22879 Stawikowska R. Cudic M. Giulianotti M. Houghten R.A. Fields G.B. Minond D. Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates J. Biol. Chem 2013 288 22871 2287910.1074/jbc.M113.462267382937023779109Search in Google Scholar

[9]Jones J.C., Rustagi S., Dempsey P.J.: ADAM proteases and gastrointestinal function. Annu. Rev. Physiol., 2016; 78: 243-276 Jones J.C. Rustagi S. Dempsey P.J. ADAM proteases and gastrointestinal function Annu. Rev. Physiol 2016 78 243 27610.1146/annurev-physiol-021014-071720492719426667078Search in Google Scholar

[10]Zhou Z., Ran Y.L., Hu H., Pan J., Li Z.F., Chen L.Z., Sun L.C., Peng L., Zhao X.L., Yu L. i wsp.: TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression. Clin. Exp. Metastasis, 2008; 25: 537-548 Zhou Z. Ran Y.L. Hu H. Pan J. Li Z.F. Chen L.Z. Sun L.C. Peng L. Zhao X.L. Yu L. i wsp TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression Clin. Exp. Metastasis 2008 25 537 54810.1007/s10585-008-9168-018365756Search in Google Scholar

[11]Liu H.B., Zhu Y., Yang Q.C., Shen Y., Zhang X.J., Chen H.: Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma. Genet. Mol. Res., 2015; 14: 43914398 Liu H.B. Zhu Y. Yang Q.C. Shen Y. Zhang X.J. Chen H. Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma Genet. Mol. Res 2015 14 4391439810.4238/2015.April.30.1225966212Search in Google Scholar

[12]Lo P.H., Lung H.L., Cheung A.K., Apte S.S., Chan K.W., Kwong F.M., Ko J.M., Cheng Y., Law S., Srivastava G. i wsp.: Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res., 2010; 70: 5567-5576 Lo P.H. Lung H.L. Cheung A.K. Apte S.S. Chan K.W. Kwong F.M. Ko J.M. Cheng Y. Law S. Srivastava G. i wsp Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis Cancer Res 2010 70 5567 557610.1158/0008-5472.CAN-09-4510289644420551050Search in Google Scholar

[13]Kauttu T., Mustonen H., Vainionpää S., Krogerus L., Ilonen I., Räsänen J., Salo J., Puolakkainen P.: Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma. Clin. Transl. Oncol., 2017; 19: 58-66 Kauttu T. Mustonen H. Vainionpää S. Krogerus L. Ilonen I. Räsänen J. Salo J. Puolakkainen P. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma Clin. Transl. Oncol 2017 19 58 6610.1007/s12094-016-1503-327026568Search in Google Scholar

[14]Yoshimura T., Tomita T., Dixon M.F., Axon A.T., Robinson P.A., Crabtree J.E.: ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori – infected, normal, and neoplastic gastric mucosa. J. Infect. Dis., 2002; 185: 332-340 Yoshimura T. Tomita T. Dixon M.F. Axon A.T. Robinson P.A. Crabtree J.E. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori – infected, normal, and neoplastic gastric mucosa J. Infect. Dis 2002 185 332 34010.1086/33819111807715Search in Google Scholar

[15]Wang Y.Y., Ye Z.Y., Li L., Zhao Z.S., Shao Q.S., Tao H.Q.: ADAM 10 is associated with gastric cancer progression and prognosis of patients. J. Surg. Oncol., 2011; 103: 116-123 Wang Y.Y. Ye Z.Y. Li L. Zhao Z.S. Shao Q.S. Tao H.Q. ADAM 10 is associated with gastric cancer progression and prognosis of patients J. Surg. Oncol 2011 103 116 12310.1002/jso.2178121259244Search in Google Scholar

[16]Shou Z.X., Jin X., Zhao Z.S.: Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann. Surg., 2012; 256: 1014-1022 Shou Z.X. Jin X. Zhao Z.S. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer Ann. Surg 2012 256 1014 102210.1097/SLA.0b013e3182592f5622668812Search in Google Scholar

[17]Zhang T.C., Zhu W.G., Huang M.D., Fan R.H., Chen X.F.: Prognostic value of ADAM17 in human gastric cancer. Med. Oncol., 2012; 29: 2684-2690 Zhang T.C. Zhu W.G. Huang M.D. Fan R.H. Chen X.F. Prognostic value of ADAM17 in human gastric cancer Med. Oncol 2012 29 2684 269010.1007/s12032-011-0125-422139867Search in Google Scholar

[18]Aydin D., Bilici A., Yavuzer D., Kefeli U., Tan A., Ercelep O., Mert A., Yuksel S., Ozcelik M., Isik D. i wsp.: Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Clin. Transl. Oncol., 2015; 17: 604-611 Aydin D. Bilici A. Yavuzer D. Kefeli U. Tan A. Ercelep O. Mert A. Yuksel S. Ozcelik M. Isik D. i wsp Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy Clin. Transl. Oncol 2015 17 604 61110.1007/s12094-015-1283-125786367Search in Google Scholar

[19]Li W., Wang D., Sun X., Zhang Y., Wang L., Suo J.: ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways. Int. J. Mol. Med., 2019; 43: 914-926 Li W. Wang D. Sun X. Zhang Y. Wang L. Suo J. ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways Int. J. Mol. Med 2019 43 914 92610.3892/ijmm.2018.4028631766630569104Search in Google Scholar

[20]Ebi M., Kataoka H., Shimura T., Kubota E., Hirata Y., Mizushima T., Mizoshita T., Tanaka M., Mabuchi M., Tsukamoto H. i wsp.: TGFβ induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells. Biochem. Biophys. Res. Commun., 2010; 402: 449-454 Ebi M. Kataoka H. Shimura T. Kubota E. Hirata Y. Mizushima T. Mizoshita T. Tanaka M. Mabuchi M. Tsukamoto H. i wsp TGFβ induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells Biochem. Biophys. Res. Commun 2010 402 449 45410.1016/j.bbrc.2010.09.13020934403Search in Google Scholar

[21]Nakagawa M., Nabeshima K., Asano S., Hamasaki M., Uesugi N., Tani H., Yamashita Y., Iwasaki H.: Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: Coexpression with EGFR and EGFR ligands. Cancer Sci., 2009; 100: 654-662 Nakagawa M. Nabeshima K. Asano S. Hamasaki M. Uesugi N. Tani H. Yamashita Y. Iwasaki H. Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: Coexpression with EGFR and EGFR ligands Cancer Sci 2009 100 654 66210.1111/j.1349-7006.2009.01089.x19298600Search in Google Scholar

[22]Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., Röcken C.: The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. J. Oncol., 2005; 26: 17-24 Carl-McGrath S. Lendeckel U. Ebert M. Roessner A. Röcken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer Int. J. Oncol 2005 26 17 2410.3892/ijo.26.1.17Search in Google Scholar

[23]Kim K.E., Song H., Hahm C., Yoon S.Y., Park S., Lee H.R., Hur D.Y., Kim T., Kim C.H., Bang S.I. i wsp.: Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J. Immunol., 2009; 182: 3548-3555 Kim K.E. Song H. Hahm C. Yoon S.Y. Park S. Lee H.R. Hur D.Y. Kim T. Kim C.H. Bang S.I. i wsp Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer J. Immunol 2009 182 3548 355510.4049/jimmunol.080169519265133Search in Google Scholar

[24]Kim J.M., Jeung H.C., Rha S.Y., Yu E.J., Kim T.S., Shin Y.K., Zhang X., Park K.H., Park S.W., Chung H.C. i wsp.: The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Mol. Cancer Ther., 2014; 13: 3074-3085 Kim J.M. Jeung H.C. Rha S.Y. Yu E.J. Kim T.S. Shin Y.K. Zhang X. Park K.H. Park S.W. Chung H.C. i wsp The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression Mol. Cancer Ther 2014 13 3074 308510.1158/1535-7163.MCT-13-1001425846325344581Search in Google Scholar

[25]Wang J., Zhou Y., Fei X., Chen X., Yan J., Liu B., Zhu Z.: ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. Oncol. Rep., 2017; 37: 2033-2040 Wang J. Zhou Y. Fei X. Chen X. Yan J. Liu B. Zhu Z. ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126 Oncol. Rep 2017 37 2033 204010.3892/or.2017.546028260063Search in Google Scholar

[26]Huang J., Bai Y., Huo L., Xiao J., Fan X., Yang Z., Chen H., Yang Z.: Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer. Transl. Res., 2015; 166: 602-613 Huang J. Bai Y. Huo L. Xiao J. Fan X. Yang Z. Chen H. Yang Z. Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer Transl. Res 2015 166 602 61310.1016/j.trsl.2015.05.00126024798Search in Google Scholar

[27]Chung H.W., Kim J.J., Choi J.I., Lee H.R., Lim J.B.: A disintegrin and metalloproteinase 8 as a potential blood biomarker for early diagnosis of gastric cancer. Yonsei Med. J., 2019; 60: 713-719 Chung H.W. Kim J.J. Choi J.I. Lee H.R. Lim J.B. A disintegrin and metalloproteinase 8 as a potential blood biomarker for early diagnosis of gastric cancer Yonsei Med. J 2019 60 713 71910.3349/ymj.2019.60.8.713666044531347325Search in Google Scholar

[28]Chen H., Wang S.: Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells in vitro. Oncol. Lett., 2018; 16: 1483-1490 Chen H. Wang S. Clinical significance of ADAM29 promoting the invasion and growth of gastric cancer cells in vitro Oncol. Lett 2018 16 1483 149010.3892/ol.2018.8838603646530008827Search in Google Scholar

[29]Ilic M, Ilic I.: Epidemiology of pancreatic cancer. World J. Gastroenterol., 2016; 22: 9694-9705 Ilic M Ilic I. Epidemiology of pancreatic cancer World J. Gastroenterol 2016 22 9694 970510.3748/wjg.v22.i44.9694512497427956793Search in Google Scholar

[30]Stewart B.W., Wild C.P.: World cancer report 2014. International Agency for Research on Cancer, Lyon 2014 Stewart B.W. Wild C.P. World cancer report 2014. International Agency for Research on Cancer Lyon 2014Search in Google Scholar

[31]Gaida M.M., Haag N., Günther F., Tschaharganeh D.F., Schirmacher P., Friess H., Giese N.A., Schmidt J., Wente M.N.: Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int. J. Mol. Med., 2010; 26: 281-288 Gaida M.M. Haag N. Günther F. Tschaharganeh D.F. Schirmacher P. Friess H. Giese N.A. Schmidt J. Wente M.N. Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma Int. J. Mol. Med 2010 26 281 28810.3892/ijmm_00000463Search in Google Scholar

[32]Ringel J., Jesnowski R., Moniaux N., Lüttges J., Ringel J., Choudhury A., Batra S.K., Klöppel G., Löhr M.: Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res., 2006; 66: 9045-9053 Ringel J. Jesnowski R. Moniaux N. Lüttges J. Ringel J. Choudhury A. Batra S.K. Klöppel G. Löhr M. Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-α converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma Cancer Res 2006 66 9045 905310.1158/0008-5472.CAN-05-328716982746Search in Google Scholar

[33]Valkovskaya N., Kayed H., Felix K., Hartmann D., Giese N.A., Osinsky S.P., Friess H., Kleeff J.: ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J. Cell. Mol. Med., 2007; 11: 1162-1174 Valkovskaya N. Kayed H. Felix K. Hartmann D. Giese N.A. Osinsky S.P. Friess H. Kleeff J. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer J. Cell. Mol. Med 2007 11 1162 117410.1111/j.1582-4934.2007.00082.x440127717979891Search in Google Scholar

[34]Valkovskaya N.V: Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines. Exp. Oncol., 2008; 30: 129132 Valkovskaya N.V Hypoxia-dependent expression of ADAM8 in human pancreatic cancer cell lines Exp. Oncol 2008 30 129132Search in Google Scholar

[35]Puolakkainen P., Koski A., Vainionpää S., Shen Z., Repo H., Kemppainen E., Mustonen H., Seppänen H.: Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Med. Oncol., 2014; 31: 884 Puolakkainen P. Koski A. Vainionpää S. Shen Z. Repo H. Kemppainen E. Mustonen H. Seppänen H. Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression Med. Oncol 2014 31 88410.1007/s12032-014-0884-924526468Search in Google Scholar

[36]Gao Y., Yu X., Zhang F., Dai J.: Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8. J. Hepatobiliary Pancreat. Sci., 2019; 26: 219-226 Gao Y. Yu X. Zhang F. Dai J. Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8 J. Hepatobiliary Pancreat. Sci 2019 26 219 22610.1002/jhbp.62430945470Search in Google Scholar

[37]Grützmann R., Lüttges J., Sipos B., Ammerpohl O., Dobrowolski F., Alldinger I., Kersting S., Ockert D., Koch R., Kalthoff H. i wsp.: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer, 2004; 90: 1053-1058 Grützmann R. Lüttges J. Sipos B. Ammerpohl O. Dobrowolski F. Alldinger I. Kersting S. Ockert D. Koch R. Kalthoff H. i wsp ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma Br. J. Cancer 2004 90 1053 105810.1038/sj.bjc.6601645240962514997207Search in Google Scholar

[38]Oria V.O., Lopatta P., Schmitz T., Preca B.T., Nyström A., Conrad C., Bartsch J.W., Kulemann B., Hoeppner J., Maurer J. i wsp.: ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma. Mol. Oncol., 2019; 13: 456-479 Oria V.O. Lopatta P. Schmitz T. Preca B.T. Nyström A. Conrad C. Bartsch J.W. Kulemann B. Hoeppner J. Maurer J. i wsp ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma Mol. Oncol 2019 13 456 47910.1002/1878-0261.12426636037330556643Search in Google Scholar

[39]Duan X., Mao X., Sun W.: ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells. Mol. Med. Rep., 2013; 7: 991-997 Duan X. Mao X. Sun W. ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells Mol. Med. Rep 2013 7 991 99710.3892/mmr.2013.127223314034Search in Google Scholar

[40]Woods N., Trevino J., Coppola D., Chellappan S., Yang S., Padmanabhan J.: Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling. Oncotarget, 2015; 6: 35931-35948 Woods N. Trevino J. Coppola D. Chellappan S. Yang S. Padmanabhan J. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling Oncotarget 2015 6 35931 3594810.18632/oncotarget.5933474215226440150Search in Google Scholar

[41]Ye J., Yuen S.M., Murphy G., Xie R., Kwok H.F.: Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo. Eur. J. Pharm. Sci., 2017; 110: 62-69 Ye J. Yuen S.M. Murphy G. Xie R. Kwok H.F. Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo. Eur J. Pharm. Sci 2017 110 62 6910.1016/j.ejps.2017.05.057Search in Google Scholar

[42]Schlomann U., Koller G., Conrad C., Ferdous T., Golfi P., Garcia A.M., Höfling S., Parsons M., Costa P., Soper R. i wsp.: ADAM8 as a drug target in pancreatic cancer. Nat. Commun., 2015; 6: 6175 Schlomann U. Koller G. Conrad C. Ferdous T. Golfi P. Garcia A.M. Höfling S. Parsons M. Costa P. Soper R. i wsp ADAM8 as a drug target in pancreatic cancer Nat. Commun 2015 6 617510.1038/ncomms7175501412325629724Search in Google Scholar

[43]Moss M.L., Minond D.: Recent advances in ADAM17 research: A promising target for cancer and inflammation. Mediators Inflamm., 2017; 2017: 9673537 Moss M.L. Minond D. Recent advances in ADAM17 research: A promising target for cancer and inflammation Mediators Inflamm 2017 2017 967353710.1155/2017/9673537568826029230082Search in Google Scholar

[44]Terzić J., Grivennikov S., Karin E., Karin M.: Inflammation and colon cancer. Gastroenterology, 2010; 138: 2101-2114 Terzić J. Grivennikov S. Karin E. Karin M. Inflammation and colon cancer Gastroenterology 2010 138 2101 211410.1053/j.gastro.2010.01.05820420949Search in Google Scholar

[45]Blanchot-Jossic F., Jarry A., Masson D., Bach-Ngohou K., Paineau J., Denis M.G., Laboisse C.L., Mosnier J.F.: Up-regulated expression of ADAM17 in human colon carcinoma: Co-expression with EGFR in neoplastic and endothelial cells. J. Pathol., 2005; 207: 156-163 Blanchot-Jossic F. Jarry A. Masson D. Bach-Ngohou K. Paineau J. Denis M.G. Laboisse C.L. Mosnier J.F. Up-regulated expression of ADAM17 in human colon carcinoma: Co-expression with EGFR in neoplastic and endothelial cells J. Pathol 2005 207 156 16310.1002/path.181416041691Search in Google Scholar

[46]Das S., Czarnek M., Bzowska M., Mężyk-Kopeć R., Stalińska K., Wyroba B., Sroka J., Jucha J., Deneka D., Stokłosa P. i wsp.: ADAM17 silencing in mouse colon carcinoma cells: The effect on tumoricidal cytokines and angiogenesis. PLoS One, 2012; 7: e50791 Das S. Czarnek M. Bzowska M. Mężyk-Kopeć R. Stalińska K. Wyroba B. Sroka J. Jucha J. Deneka D. Stokłosa P. i wsp ADAM17 silencing in mouse colon carcinoma cells: The effect on tumoricidal cytokines and angiogenesis PLoS One 2012 7 e5079110.1371/journal.pone.0050791351946923251384Search in Google Scholar

[47]Lin H.M., Chatterjee A., Lin Y.H., Anjomshoaa A., Fukuzawa R., McCall J.L., Reeve A.E.: Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol. Rep., 2007; 17: 1541-1549 Lin H.M. Chatterjee A. Lin Y.H. Anjomshoaa A. Fukuzawa R. McCall J.L. Reeve A.E. Genome wide expression profiling identifies genes associated with colorectal liver metastasis Oncol. Rep 2007 17 1541 154910.3892/or.17.6.154117487416Search in Google Scholar

[48]Van Schaeybroeck S., Kyula J.N., Fenton A., Fenning C.S., Sasazuki T., Shirasawa S., Longley D.B., Johnston P.G.: Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res., 2011; 71: 1071-1080 Van Schaeybroeck S. Kyula J.N. Fenton A. Fenning C.S. Sasazuki T. Shirasawa S. Longley D.B. Johnston P.G. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17 Cancer Res 2011 71 1071 108010.1158/0008-5472.CAN-10-0714307312621148749Search in Google Scholar

[49]Rios-Doria J., Sabol D., Chesebrough J., Stewart D., Xu L., Tammali R., Cheng L., Du Q., Schifferli K., Rothstein R. i wsp.: A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways. Mol. Cancer Ther., 2015; 14: 1637-1649 Rios-Doria J. Sabol D. Chesebrough J. Stewart D. Xu L. Tammali R. Cheng L. Du Q. Schifferli K. Rothstein R. i wsp A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways Mol. Cancer Ther 2015 14 1637 164910.1158/1535-7163.MCT-14-104025948294Search in Google Scholar

[50]Dempsey P.J.: Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis. Biochim. Biophys. Acta, 2017; 1864: 22282239 Dempsey P.J. Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis Biochim. Biophys. Acta 2017 1864 2228223910.1016/j.bbamcr.2017.07.011563258928739265Search in Google Scholar

[51]Knösel T., Emde A., Schlüns K., Chen Y., Jürchott K., Krause M., Dietel M., Petersen I.: Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia, 2005; 7: 741-747 Knösel T. Emde A. Schlüns K. Chen Y. Jürchott K. Krause M. Dietel M. Petersen I. Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer Neoplasia 2005 7 741 74710.1593/neo.05178150188316207476Search in Google Scholar

[52]Walkiewicz K., Strzelczyk J., Waniczek D., Biernacki K., Muc-Wierzgoń M., Copija A., Nowakowska-Zajdel E.: Adamalysines as biomarkers and a potential target of therapy in colorectal cancer patients: Preliminary results. Dis. Markers, 2019; 2019: 5035234 Walkiewicz K. Strzelczyk J. Waniczek D. Biernacki K. Muc-Wierzgoń M. Copija A. Nowakowska-Zajdel E. Adamalysines as biomarkers and a potential target of therapy in colorectal cancer patients: Preliminary results Dis. Markers 2019 2019 503523410.1155/2019/5035234674517331565100Search in Google Scholar

[53]Nowakowska-Zajdel E., Mazurek U., Wierzgoń J., Kokot T., Fatyga E., Ziółko E., Klakla K., Błazelonis A., Waniczek D., Głogowski Ł. i wsp.: Expression of ADAM28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary report. Int. J. Immunopathol. Pharmacol., 2013; 26: 223-228 Nowakowska-Zajdel E. Mazurek U. Wierzgoń J. Kokot T. Fatyga E. Ziółko E. Klakla K. Błazelonis A. Waniczek D. Głogowski Ł. i wsp Expression of ADAM28 and IGFBP-3 genes in patients with colorectal cancer – a preliminary report Int. J. Immunopathol. Pharmacol 2013 26 223 22810.1177/03946320130260012223527725Search in Google Scholar

[54]Mochizuki S., Ao T., Sugiura T., Yonemura K., Shiraishi T., Kajiwara Y., Okamoto K., Shinto E., Okada Y., Ueno H.: Expression and function of a disintegrin and metalloproteinases in cancerassociated fibroblasts of colorectal cancer. Digestion, 2020; 101: 18-24 Mochizuki S. Ao T. Sugiura T. Yonemura K. Shiraishi T. Kajiwara Y. Okamoto K. Shinto E. Okada Y. Ueno H. Expression and function of a disintegrin and metalloproteinases in cancerassociated fibroblasts of colorectal cancer Digestion 2020 101 18 2410.1159/00050408731722362Search in Google Scholar

[55]Yang Z., Bai Y., Huo L., Chen H., Huang J., Li J., Fan X., Yang Z., Wang L., Wang J.: Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer, 2014; 14: 568 Yang Z. Bai Y. Huo L. Chen H. Huang J. Li J. Fan X. Yang Z. Wang L. Wang J. Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer BMC Cancer 2014 14 56810.1186/1471-2407-14-568414108825098630Search in Google Scholar

[56]Hirao T., Nanba D., Tanaka M., Ishiguro H., Kinugasa Y., Doki Y., Yano M., Matsuura N., Monden M., Higashiyama S.: Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp. Cell Res., 2006; 312: 331-339 Hirao T. Nanba D. Tanaka M. Ishiguro H. Kinugasa Y. Doki Y. Yano M. Matsuura N. Monden M. Higashiyama S. Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells Exp. Cell Res 2006 312 331 33910.1016/j.yexcr.2005.10.03216336960Search in Google Scholar

[57]Mazzocca A., Coppari R., De Franco R., Cho J.Y., Libermann T.A., Pinzani M., Toker A.: A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res., 2005; 65: 4728-4738 Mazzocca A. Coppari R. De Franco R. Cho J.Y. Libermann T.A. Pinzani M. Toker A. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions Cancer Res 2005 65 4728 473810.1158/0008-5472.CAN-04-444915930291Search in Google Scholar

[58]Toquet C., Colson A., Jarry A., Bezieau S., Volteau C., Boisseau P., Merlin D., Laboisse C.L., Mosnier J.F.: ADAM15 to α5β1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis. Int. J. Cancer, 2012; 130: 278-287 Toquet C. Colson A. Jarry A. Bezieau S. Volteau C. Boisseau P. Merlin D. Laboisse C.L. Mosnier J.F. ADAM15 to α5β1 integrin switch in colon carcinoma cells: A late event in cancer progression associated with tumor dedifferentiation and poor prognosis Int. J. Cancer 2012 130 278 28710.1002/ijc.2589121190186Search in Google Scholar

[59]Wang J., Li H., Wang Y., Wang L., Yan X., Zhang D., Ma X., Du Y., Liu X., Yang Y.: MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28. Oncotarget, 2016; 7: 70194-70210 Wang J. Li H. Wang Y. Wang L. Yan X. Zhang D. Ma X. Du Y. Liu X. Yang Y. MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28 Oncotarget 2016 7 70194 7021010.18632/oncotarget.12169534254627661126Search in Google Scholar

[60]Li L.X., Lam I.H., Liang F.F., Yi S.P., Ye L.F., Wang J.T., Guo W.W., Xu M.: MiR-198 affects the proliferation and apoptosis of colorectal cancer through regulation of ADAM28/JAK-STAT signaling pathway. Eur. Rev. Med. Pharmacol. Sci., 2019; 23: 1487-1493 Li L.X. Lam I.H. Liang F.F. Yi S.P. Ye L.F. Wang J.T. Guo W.W. Xu M. MiR-198 affects the proliferation and apoptosis of colorectal cancer through regulation of ADAM28/JAK-STAT signaling pathway Eur. Rev. Med. Pharmacol. Sci 2019 23 1487 1493Search in Google Scholar

[61]Zhang Q., Yu L., Qin D., Huang R., Jiang X., Zou C., Tang Q., Chen Y., Wang G., Wang X., Gao X.: Role of microRNA-30c targeting ADAM19 in colorectal cancer. PLoS One, 2015; 10: e0120698 Zhang Q. Yu L. Qin D. Huang R. Jiang X. Zou C. Tang Q. Chen Y. Wang G. Wang X. Gao X. Role of microRNA-30c targeting ADAM19 in colorectal cancer PLoS One 2015 10 e012069810.1371/journal.pone.0120698437075725799050Search in Google Scholar

[62]Fu Q., Cheng J., Zhang J., Zhang Y., Chen X., Luo S., Xie J.: MiR-20b reduces 5-FU resistance by suppressing the ADAM9/ EGFR signaling pathway in colon cancer. Oncol. Rep., 2017; 37: 123-130 Fu Q. Cheng J. Zhang J. Zhang Y. Chen X. Luo S. Xie J. MiR-20b reduces 5-FU resistance by suppressing the ADAM9/ EGFR signaling pathway in colon cancer Oncol. Rep 2017 37 123 13010.3892/or.2016.525927878272Search in Google Scholar

[63]Carloni V., Mazzocca A., Mello T., Galli A., Capaccioli S.: Cell fusion promotes chemoresistance in metastatic colon carcinoma. Oncogene, 2013; 32: 2649-2660 Carloni V. Mazzocca A. Mello T. Galli A. Capaccioli S. Cell fusion promotes chemoresistance in metastatic colon carcinoma Oncogene 2013 32 2649 266010.1038/onc.2012.26822751128Search in Google Scholar

[64]Kyula J.N., Van Schaeybroeck S., Doherty J., Fenning C.S., Longley D.B., Johnston P.G.: Chemotherapy-induced activation of ADAM-17: A novel mechanism of drug resistance in colorectal cancer. Clin. Cancer Res., 2010; 16: 3378-3389 Kyula J.N. Van Schaeybroeck S. Doherty J. Fenning C.S. Longley D.B. Johnston P.G. Chemotherapy-induced activation of ADAM-17: A novel mechanism of drug resistance in colorectal cancer Clin. Cancer Res 2010 16 3378 338910.1158/1078-0432.CCR-10-0014289655020570921Search in Google Scholar